Triple-negative breast cancer molecular subtyping and treatment progress

被引：1734
作者：
Yin, Li [1 ,2 ,3 ,4 ]
Duan, Jiang-Jie [1 ,2 ,3 ,4 ]
Bian, Xiu-Wu [2 ,3 ,4 ]
Yu, Shi-cang [1 ,2 ,3 ,4 ]
机构：
[1] Army Med Univ, Third Mil Med Univ, Dept Stem Cell & Regenerat Med, Southwest Hosp, Chongqing 400038, Peoples R China
[2] Army Med Univ, Third Mil Med Univ, Inst Pathol, Southwest Hosp, Chongqing 400038, Peoples R China
[3] Army Med Univ, Third Mil Med Univ, Southwest Canc Ctr, Southwest Hosp, Chongqing 400038, Peoples R China
[4] Minist Educ, Key Lab Canc Immunopathol, Chongqing 400038, Peoples R China
来源：
BREAST CANCER RESEARCH | 2020年 / 22卷 / 01期
基金：
中国国家自然科学基金;
关键词：
Triple-negative breast cancer; Molecular subtype; Therapeutic target; Therapeutic regimen; BASAL-LIKE SUBTYPE; ADJUVANT CHEMOTHERAPY; NEOADJUVANT PACLITAXEL; CLINICAL-FEATURES; PHASE-II; IDENTIFICATION; EXPRESSION; SURVIVAL; OUTCOMES; PATHWAY;
D O I：
10.1186/s13058-020-01296-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Triple-negative breast cancer (TNBC), a specific subtype of breast cancer that does not express estrogen receptor (ER), progesterone receptor (PR), or human epidermal growth factor receptor 2 (HER-2), has clinical features that include high invasiveness, high metastatic potential, proneness to relapse, and poor prognosis. Because TNBC tumors lack ER, PR, and HER2 expression, they are not sensitive to endocrine therapy or HER2 treatment, and standardized TNBC treatment regimens are still lacking. Therefore, development of new TNBC treatment strategies has become an urgent clinical need. By summarizing existing treatment regimens, therapeutic drugs, and their efficacy for different TNBC subtypes and reviewing some new preclinical studies and targeted treatment regimens for TNBC, this paper aims to provide new ideas for TNBC treatment.
引用
收藏
页数：13
相关论文
共 82 条
[21]   Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy [J].
Farmer, H ;
McCabe, N ;
Lord, CJ ;
Tutt, ANJ ;
Johnson, DA ;
Richardson, TB ;
Santarosa, M ;
Dillon, KJ ;
Hickson, I ;
Knights, C ;
Martin, NMB ;
Jackson, SP ;
Smith, GCM ;
Ashworth, A .
NATURE, 2005, 434 (7035) :917-921
[22]   Identification of molecular apocrine breast tumours by microarray analysis [J].
Farmer, P ;
Bonnefoi, H ;
Becette, V ;
Tubiana-Hulin, M ;
Fumoleau, P ;
Larsimont, D ;
MacGrogan, G ;
Bergh, J ;
Cameron, D ;
Goldstein, D ;
Duss, S ;
Nicoulaz, AL ;
Brisken, C ;
Fiche, M ;
Delorenzi, M ;
Iggo, R .
ONCOGENE, 2005, 24 (29) :4660-4671
[23]   Programmed Cell Death 1 (PD-1) and Its Ligand (PD-L1) in Common Cancers and Their Correlation with Molecular Cancer Type [J].
Gatalica, Zoran ;
Snyder, Carrie ;
Maney, Todd ;
Ghazalpour, Anatole ;
Holterman, Daniel A. ;
Xiao, Nianqing ;
Overberg, Peggy ;
Rose, Inga ;
Basu, Gargi D. ;
Vranic, Semir ;
Lynch, Henry T. ;
Von Hoff, Daniel D. ;
Hamid, Omid .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2014, 23 (12) :2965-2970
[24]   Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study [J].
Gelmon, Karen A. ;
Tischkowitz, Marc ;
Mackay, Helen ;
Swenerton, Kenneth ;
Robidoux, Andre ;
Tonkin, Katia ;
Hirte, Hal ;
Huntsman, David ;
Clemons, Mark ;
Gilks, Blake ;
Yerushalmi, Rinat ;
Macpherson, Euan ;
Carmichael, James ;
Oza, Amit .
LANCET ONCOLOGY, 2011, 12 (09) :852-861
[25]  
Gibson GR, 2005, AM SURGEON, V71, P725
[26]  
Giltnane JM, 2014, DISCOV MED, V17, P275
[27]   Triple-negative breast cancer-current status and future directions [J].
Gluz, O. ;
Liedtke, C. ;
Gottschalk, N. ;
Pusztai, L. ;
Nitz, U. ;
Harbeck, N. .
ANNALS OF ONCOLOGY, 2009, 20 (12) :1913-1927
[28]   Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 [J].
Goldhirsch, A. ;
Winer, E. P. ;
Coates, A. S. ;
Gelber, R. D. ;
Piccart-Gebhart, M. ;
Thuerlimann, B. ;
Senn, H. -J. .
ANNALS OF ONCOLOGY, 2013, 24 (09) :2206-2223
[29]   Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer [J].
Gonzalez-Angulo, Ana M. ;
Timms, Kirsten M. ;
Liu, Shuying ;
Chen, Huiqin ;
Litton, Jennifer K. ;
Potter, Jennifer ;
Lanchbury, Jerry S. ;
Stemke-Hale, Katherine ;
Hennessy, Bryan T. ;
Arun, Banu K. ;
Hortobagyi, Gabriel N. ;
Do, Kim-Anh ;
Mills, Gordon B. ;
Meric-Bernstam, Funda .
CLINICAL CANCER RESEARCH, 2011, 17 (05) :1082-1089
[30]   Androgen Receptor Levels and Association with PIK3CA Mutations and Prognosis in Breast Cancer [J].
Gonzalez-Angulo, Ana M. ;
Stemke-Hale, Katherine ;
Palla, Shana L. ;
Carey, Mark ;
Agarwal, Roshan ;
Meric-Berstam, Funda ;
Traina, Tiffany A. ;
Hudis, Clifford ;
Hortobagyi, Gabriel N. ;
Gerald, William L. ;
Mills, Gordon B. ;
Hennessy, Bryan T. .
CLINICAL CANCER RESEARCH, 2009, 15 (07) :2472-2478
123456789